Isofol Medical AB (publ) (ISOFOL.ST)
SEK 2.53
(3.06%)
SEK 2.53
(3.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -138.14 Million SEK | 25.98% |
| 2022 | -186.63 Million SEK | 50.6% |
| 2021 | -377.79 Million SEK | -233.52% |
| 2020 | -113.27 Million SEK | 8.81% |
| 2019 | -124.22 Million SEK | 54.48% |
| 2018 | -272.89 Million SEK | 23.63% |
| 2017 | -357.33 Million SEK | -1769.47% |
| 2016 | -19.11 Million SEK | -162.05% |
| 2015 | -7.29 Million SEK | 0.0% |
| 2011 | -8.39 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -128.49 Million SEK | 6.99% |
| 2024 Q2 | -119.15 Million SEK | 7.27% |
| 2023 Q1 | -163.96 Million SEK | 12.15% |
| 2023 Q2 | -156.76 Million SEK | 4.39% |
| 2023 Q3 | -144.22 Million SEK | 8.0% |
| 2023 Q4 | -138.14 Million SEK | 4.21% |
| 2023 FY | -138.14 Million SEK | 25.98% |
| 2022 Q2 | -251.24 Million SEK | 19.34% |
| 2022 Q1 | -311.46 Million SEK | 17.56% |
| 2022 FY | -186.63 Million SEK | 50.6% |
| 2022 Q4 | -186.63 Million SEK | -15.26% |
| 2022 Q3 | -161.92 Million SEK | 35.55% |
| 2021 Q3 | -346.17 Million SEK | 34.67% |
| 2021 Q1 | -76.36 Million SEK | 32.59% |
| 2021 Q2 | -529.91 Million SEK | -593.93% |
| 2021 FY | -377.79 Million SEK | -233.52% |
| 2021 Q4 | -377.79 Million SEK | -9.13% |
| 2020 FY | -113.27 Million SEK | 8.81% |
| 2020 Q4 | -113.27 Million SEK | 25.27% |
| 2020 Q2 | -183.35 Million SEK | -162.45% |
| 2020 Q1 | -69.86 Million SEK | 43.76% |
| 2020 Q3 | -151.58 Million SEK | 17.33% |
| 2019 Q3 | -187.62 Million SEK | 14.3% |
| 2019 Q2 | -218.93 Million SEK | 9.72% |
| 2019 FY | -124.22 Million SEK | 54.48% |
| 2019 Q4 | -124.22 Million SEK | 33.79% |
| 2019 Q1 | -242.5 Million SEK | 11.14% |
| 2018 Q1 | -341.1 Million SEK | 4.54% |
| 2018 Q2 | -244.98 Million SEK | 28.18% |
| 2018 Q4 | -272.89 Million SEK | -22.4% |
| 2018 FY | -272.89 Million SEK | 23.63% |
| 2018 Q3 | -222.95 Million SEK | 8.99% |
| 2017 Q1 | -5.74 Million SEK | 69.94% |
| 2017 FY | -357.33 Million SEK | -1769.47% |
| 2017 Q4 | -357.33 Million SEK | -1433.02% |
| 2017 Q3 | -23.3 Million SEK | 94.06% |
| 2017 Q2 | -392.23 Million SEK | -6727.43% |
| 2016 Q1 | 7.29 Million SEK | 200.0% |
| 2016 Q4 | -19.11 Million SEK | 0.0% |
| 2016 FY | -19.11 Million SEK | -162.05% |
| 2015 Q4 | -7.29 Million SEK | 0.0% |
| 2015 FY | -7.29 Million SEK | 0.0% |
| 2011 FY | -8.39 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -176.18% |
| Ziccum AB (publ) | -2.13 Million SEK | -6364.577% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -624.806% |
| BioArctic AB (publ) | -606.58 Million SEK | 77.225% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -176.661% |
| Mendus AB (publ) | -96.29 Million SEK | -43.465% |
| Genovis AB (publ.) | -43.94 Million SEK | -214.394% |
| Intervacc AB (publ) | -88.16 Million SEK | -56.701% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 773.564% |
| Active Biotech AB (publ) | -33.2 Million SEK | -316.108% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 359.564% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -250.79% |
| Aptahem AB (publ) | 2.9 Million SEK | 4849.57% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 58.591% |
| Kancera AB (publ) | -45.69 Million SEK | -202.346% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 58.018% |
| Fluicell AB (publ) | -2.76 Million SEK | -4899.928% |
| Saniona AB (publ) | 40.44 Million SEK | 441.553% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -332.7% |
| Biovica International AB (publ) | -58.73 Million SEK | -135.198% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -205.522% |
| AcouSort AB (publ) | -23.98 Million SEK | -475.953% |
| Xintela AB (publ) | -7.8 Million SEK | -1669.087% |
| Abliva AB (publ) | -57.24 Million SEK | -141.349% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 29.046% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -68.059% |
| OncoZenge AB (publ) | -12.62 Million SEK | -994.068% |
| Amniotics AB (publ) | -5.63 Million SEK | -2352.912% |
| 2cureX AB (publ) | -13.4 Million SEK | -930.724% |
| CombiGene AB (publ) | -101.44 Million SEK | -36.187% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -6292.781% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 2658.296% |
| Camurus AB (publ) | -1.16 Billion SEK | 88.145% |
| Corline Biomedical AB | -17.01 Million SEK | -712.062% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -64.967% |
| I-Tech AB | -83.26 Million SEK | -65.92% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 202.554% |
| Cyxone AB (publ) | -16.67 Million SEK | -728.722% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -147.196% |
| Biosergen AB | -1.88 Million SEK | -7236.591% |
| Cantargia AB (publ) | -139.74 Million SEK | 1.144% |
| NextCell Pharma AB | -46.79 Million SEK | -195.247% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -6.682% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -370.164% |
| Nanologica AB (publ) | -9.38 Million SEK | -1371.538% |
| SynAct Pharma AB | -61.75 Million SEK | -123.692% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -545.099% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -944.267% |
| LIDDS AB (publ) | -13.51 Million SEK | -922.41% |
| Lipum AB (publ) | -8.46 Million SEK | -1531.991% |
| BioInvent International AB (publ) | -236.3 Million SEK | 41.538% |
| Alzinova AB (publ) | -21.22 Million SEK | -550.843% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -106.438% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -2566.476% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -64.971% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -14867.281% |
| Simris Alg AB (publ) | 85.07 Million SEK | 262.384% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -68.297% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 183.183% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -564.397% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -4548.318% |